What's in PharmaEssentia's pipeline?

PharmaEssentia has 9 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with PharmaEssentia's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pharmaessentia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

PharmaEssentia — Portfolio Competitive Intelligence Brief

PharmaEssentia pipeline: 0 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
P1101 + Ribavirin	P1101 + Ribavirin	phase 3	Interferon lambda + nucleoside analog antiviral	Interferon lambda receptor (IFNLR1); viral RNA-dependent RNA polymerase	Virology / Hepatology
KX01 ointment 1%	KX01 ointment 1%	phase 3
PEG-Intron + Ribavirin	PEG-Intron + Ribavirin	phase 3	Interferon-alpha and antiviral	Interferon receptors	Hepatology

Therapeutic area mix

Hepatology · 1
Virology / Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for PharmaEssentia:

Cite this brief

Drug Landscape (2026). PharmaEssentia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmaessentia. Accessed 2026-05-14.